TY - JOUR
T1 - Comparison of combination chemotherapy programs in advanced adenocarcinoma-large cell carcinoma of the lung
T2 - A north central cancer treatment group study
AU - Krook, J. E.
AU - Fleming, T. R.
AU - Eagan, R. T.
AU - Cullinan, S.
AU - Pfeifle, D.
AU - Elliott, T.
AU - Etzell, P.
PY - 1984
Y1 - 1984
N2 - One hundred and six patients with advanced adrenocarcinoma and large cell carcinoma of the lung with no prior chemotherapy were entered in a prospectively randomized trial comparing cyclophosphamide, doxorubicin, and cisplatin versus methotrexate, doxorubicin, cyclophosphamide, and lomustine. The two regimens resulted in nearly identical regression probabilities (36% vs 34%), distributions of time to progression, and survival distributions. The major toxic effects from both regimens consisted primarily of myelosuppression and nausea and vomiting, with severe vomiting occurring more frequently in patients treated with cyclophosphamide, doxorubicin, and cisplatin (43% vs 19%).
AB - One hundred and six patients with advanced adrenocarcinoma and large cell carcinoma of the lung with no prior chemotherapy were entered in a prospectively randomized trial comparing cyclophosphamide, doxorubicin, and cisplatin versus methotrexate, doxorubicin, cyclophosphamide, and lomustine. The two regimens resulted in nearly identical regression probabilities (36% vs 34%), distributions of time to progression, and survival distributions. The major toxic effects from both regimens consisted primarily of myelosuppression and nausea and vomiting, with severe vomiting occurring more frequently in patients treated with cyclophosphamide, doxorubicin, and cisplatin (43% vs 19%).
UR - http://www.scopus.com/inward/record.url?scp=0021278752&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021278752&partnerID=8YFLogxK
M3 - Article
C2 - 6322987
AN - SCOPUS:0021278752
SN - 0361-5960
VL - 68
SP - 493
EP - 498
JO - Cancer Treatment Reports
JF - Cancer Treatment Reports
IS - 3
ER -
